💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Aeglea Bio sells off after presentation on lead candidate AEB1102; shares down 11%

Published 01/23/2018, 03:40 PM
© Reuters.  Aeglea Bio sells off after presentation on lead candidate AEB1102; shares down 11%
SYRE
-
  • Investors in thinly traded nano cap Aeglea BioTherapeutics (AGLE -10.5%) appear to be taking profits after its 88% runup since the first of December.
  • Yesterday evening, data were presented at the Keystone Symposia Tumor Metabolism Conference in Snowbird, UT on how arginine depletion with lead candidate AEB1102 (pegzilarginase) enhanced the anti-tumor activity of a PD-L1 inhibitor.
  • Pegzilarginase is an arginine degrader derived from human Arginase 1. The company says it has a potential immunogenicity advantage over microbial enzymes because its human origin makes it less likely to provoke an immune response when administered.
  • Now read: Aeglea Biotherapeutics (AGLE) Presents At BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.